Pacira BioSciences, Inc.NASDAQ: PCRX

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

· Published via Business Wire

Summary by 6ix AI

Law firm Kahn Swick & Foti, LLC (KSF), whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is investigating whether the price and process in the proposed sale of Pacira BioSciences, Inc. to Viatris Inc. are adequate, or whether the price undervalues Pacira.

Key details

  • Under the terms of the proposed transaction, Pacira shareholders would receive $36.50 in cash for each Pacira share they own.
  • The transaction is structured as a tender offer, an offer made directly to shareholders to buy their shares, and KSF says time may be of the essence.
  • KSF is inviting Pacira shareholders who believe the deal undervalues the company, or who want to discuss their legal rights, to contact it without obligation or cost.

What’s still pending

  • The sale of Pacira BioSciences, Inc. to Viatris Inc. is still a proposed transaction.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/pacira-biosciences-investor-alert-kahn-swick-and-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at (833) 538-3612, or visit https://www.ksfcounsel.com/cases/nasdaqgs-pcrx/ to learn more.

Please note that the transaction is structured as a tender offer, such that time may be of the essence.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

View source version on businesswire.com: https://www.businesswire.com/news/home/20261012418467/en/

View original source (Business Wire)Pacira BioSciences, Inc. on 6ix

Earlier from Pacira BioSciences

All Pacira BioSciences news releases